Shared on22 Aug 25Fair value Increased 21%
The sharp upward revision in the analyst price target for Vivos Therapeutics reflects markedly improved revenue growth forecasts and a lower future P/E multiple, raising fair value from $4.22 to $5.10. What's in the News Vivos Therapeutics will be unable to file its next 10-Q by the SEC deadline.
Shared on24 Apr 25Fair value Decreased 5.96%
AnalystConsensusTarget has decreased revenue growth from 22.2% to 17.5%.